John Sargent Sundy, MD, PhD

Adjunct Professor in the Department of Medicine
Member in the Duke Clinical Research Institute
Campus mail Duke Box 3278, 3854 Clinic 3N, Duke Clinic, Durham, NC 27710
Phone (919) 684-2347
Email address sundy001@mc.duke.edu

Research Theme

The focus of my research is on human-based translational studies and therapeutic trials of novel agents for inflammatory and immunologic diseases. My group has experience in mechanistic studies of environmental exposure in airway diseases; genetic analysis and gene expression studies using microarrays; airway challenge and assessment of response in the upper and lower airway and periphery; and therapeutic trials of experimental agents in Phases I-IV. Areas of focus include:

Asthma and Allergic Diseases

Research interests in asthma and allergic diseases focus upon human studies investigating the response to environmental endotoxin exposure. Using airway challenge with lipopolysaccharide and well characterized allergens, we investigate the genetic regulation of immunologic and inflammatory responses in the lung and in the periphery. This work is performed in collaboration with investigators with expertise in bench science and computational biology. In addition I participate in a number of multi-center research projects related to experimental therapeutics and genetic susceptibility to asthma and allergic diseases.

Rheumatologic Diseases

My primary research focus in rheumatologic diseases is on experimental therapeutics in chronic gout. Gout is the most common inflammatory arthritis in men, and the prevalence of disease is increasing in the population. We have led Phase I through III studies of pegloticase (PEGylated uricase) in subjects with treatment failure gout. We have initiated a new line of investigation that focuses upon IL-1 inhibition in the treatment of inflammation in acute and chronic gout.

Duke Clinical Research Institute - Multicenter Clinical Trials

I serve as the Director of Rheumatology and Allergy Research at the Duke Clinical Research Institute, a large academic research organization with expertise in the coordination of multi-center clinical trials and registries. Our objective is to develop a diverse portfolio of research registries and clinical trials in rheumatic and immunologic disease led by investigators at Duke. Currently our group is involved in programs in pediatric lupus, systemic onset JIA, gout, rheumatoid arthritis, and scleroderma.

Education and Training

  • Fellow in Allergy and Immunology, Medicine, Duke University, 1995 - 1998
  • Fellow in Rheumatology, Medicine, Duke University, 1993 - 1997
  • Medical Resident, Medicine, Duke University, 1991 - 1993
  • Ph.D., Drexel University, 1991
  • M.D., Drexel University, 1991

Publications

Chertow, Glenn M., Pablo E. Pergola, Fang Chen, Brian J. Kirby, John S. Sundy, Uptal D. Patel, and Uptal D. GS-US-223-1015 Investigators. “Effects of Selonsertib in Patients with Diabetic Kidney Disease..” J Am Soc Nephrol 30, no. 10 (October 2019): 1980–90. https://doi.org/10.1681/ASN.2018121231.

PMID
31506292
Full Text

Genovese, Mark C., Kenneth Kalunian, Jacques-Eric Gottenberg, Neelufar Mozaffarian, Beatrix Bartok, Franziska Matzkies, Jie Gao, et al. “Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial..” Jama 322, no. 4 (July 23, 2019): 315–25. https://doi.org/10.1001/jama.2019.9055.

PMID
31334793
Full Text

Moore, Camille, Rachel Z. Blumhagen, Ivana V. Yang, Avram Walts, Julie Powers, Tarik Walker, Makenna Bishop, et al. “Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis..” Am J Respir Crit Care Med 200, no. 2 (July 15, 2019): 199–208. https://doi.org/10.1164/rccm.201810-1891OC.

PMID
31034279
Full Text

Poe, Jonathan C., Wei Jia, Julie A. Di Paolo, Nancy J. Reyes, Ji Yun Kim, Hsuan Su, John S. Sundy, et al. “SYK inhibitor entospletinib prevents ocular and skin GVHD in mice..” Jci Insight 3, no. 19 (October 4, 2018). https://doi.org/10.1172/jci.insight.122430.

PMID
30282825
Full Text

Humphries, Stephen M., Jeffrey J. Swigris, Kevin K. Brown, Matthew Strand, Qi Gong, John S. Sundy, Ganesh Raghu, et al. “Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis..” Eur Respir J 52, no. 3 (September 2018). https://doi.org/10.1183/13993003.01384-2018.

PMID
30139770
Full Text

Schreiber, Stefan, Corey A. Siegel, Keith A. Friedenberg, Ziad H. Younes, Ursula Seidler, Bal R. Bhandari, Ke Wang, et al. “A phase 2, Randomized, Placebo-controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients with Moderately to Severely Active Crohn's Disease..” J Crohns Colitis, May 29, 2018. https://doi.org/10.1093/ecco-jcc/jjy070.

PMID
29846530
Full Text

Sandborn, William J., Bal R. Bhandari, Charles Randall, Ziad H. Younes, Tomasz Romanczyk, Yan Xin, Emily Wendt, et al. “Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease..” J Crohns Colitis, May 14, 2018. https://doi.org/10.1093/ecco-jcc/jjy049.

PMID
29767728
Full Text

Wang, Jennifer M., Scott H. Robertson, Ziyi Wang, Mu He, Rohan S. Virgincar, Geoffry M. Schrank, Rose Marie Smigla, et al. “Using hyperpolarized 129Xe MRI to quantify regional gas transfer in idiopathic pulmonary fibrosis..” Thorax 73, no. 1 (January 2018): 21–28. https://doi.org/10.1136/thoraxjnl-2017-210070.

PMID
28860333
Full Text

Gossage, David L., Blanka Cieslarová, Sophe Ap, Hao Zheng, Yan Xin, Preeti Lal, Guang Chen, Victoria Smith, and John S. Sundy. “Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With Rheumatoid Arthritis..” Clin Ther 40, no. 1 (January 2018): 156-165.e5. https://doi.org/10.1016/j.clinthera.2017.11.011.

PMID
29287749
Full Text

Patel, Dhavalkumar D., Christian Antoni, Steven J. Freedman, Marc C. Levesque, and John S. Sundy. “Phase 2 to phase 3 clinical trial transitions: Reasons for success and failure in immunologic diseases..” J Allergy Clin Immunol 140, no. 3 (September 2017): 685–87. https://doi.org/10.1016/j.jaci.2017.04.029.

PMID
28506849
Full Text

Pages